Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 ...

CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s ...

Boehringer Ingelheim picked a challenging day to reveal its 2024 financial results and guidance for this year. | Boehringer ...

Boehringer Ingelheim, a biopharmaceutical firm that manufactures medicine for humans and animals, has relocated to a ...

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing ...

“If we look at the past five years, Boehringer Ingelheim has invested approximately EUR 25 billion in R&D,” said Frank Hübler, Member of the Board of Managing Directors with responsibility ...

Hi there, Johns Creek! We've got your morning read ready! Read on to stay connected. ☀️ In today's newsletter: Boehringer Ingelheim moves HQ to Johns Creek Perry Greene apologizes for hate incident ...

Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate space, committing 27 million Swiss francs ($31.06 million) to a new R&D facility specifically focused on the modality.

Two years after first announcing a partnership, Boehringer Ingelheim and software firm Veeva Systems have launched Boehringer’s One Medicine platform to help the German pharma streamline its ...